Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

BioSense Inks $68 Million Deal for Neovacs’ Autoimmune Disease Vaccine in China

publication date: Feb 21, 2017
New Jersey/Suzhou-based BioSense Global has signed an option agreement with Neovacs of France for Neovacs' Phase II-stage IFNα Kinoid therapeutic vaccine candidate, a treatment for lupus and dermatomyositis. Neovacs could receive up to $68 million in upfront and milestone payments, plus sales royalties. Neovacs retains rights for other regions, except for a previously announced South Korea partnership. BioSense also receives first right of refusal in Greater China for any further IFNα Kinoid indications, including type 1 diabetes. Additional terms were not disclosed. More details....

Stock Symbol: (Paris: ALNEV)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital